Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Medtech Gets A Role In Post-Brexit Trade Deal Negotiations

Pressure ramps to broker international agreements as end of EU withdrawal period nears

Executive Summary

With the Brexit implementation period ending in four months, the UK government has launched a trade advisory group for international life sciences deal talks and given UK medtech a seat at the table.

You may also be interested in...



UKCA Mark Will Be The Post-EU Route To The British Medtech Market In January 2021

New MHRA guidance says the EU CE marking will continue to be used for devices and diagnostics in Great Britain until June 2023, and thereafter a standalone regulatory system will come into place.

UK Medtech Industry Advances Its Case For US FTA Amid Ongoing EU Talks

Securing a favorable post-Brexit free trade agreement with the US is the principal aim of the UK’s Department for International Trade, and the UK medtech industry is pressing its case for closer business links with its largest non-EU trading partner.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel